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A B S T R A C T
Purpose
To study the prognostic value for overall survival of baseline assessment of functional status,
comorbidity, and quality of life (QoL) in elderly patients with advanced non–small-cell lung
cancer treated with chemotherapy.
Patients and Methods
Data from 566 patients enrolled onto the phase III randomized Multicenter Italian Lung
Cancer in the Elderly Study (MILES) study were analyzed. Functional status was measured
as activities of daily living (ADL) and instrumental ADL (IADL). The presence of comorbidity
was assessed with a checklist of 33 items; items 29 and 30 of the European Organisation for
Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 (EORTC QLQ-C30)
were used to estimate QoL. ADL was dichotomized as none versus one or more
dependency. For IADL and QoL, three categories were defined using first and third quartiles
as cut points. Comorbidity was summarized using the Charlson scale. Analysis was
performed by Cox model, and stratified by treatment arm.
Results
Better values of baseline QoL (P  .0003) and IADL (P  .04) were significantly associated
with better prognosis, whereas ADL (P .44) and Charlson score (P .66) had no prognostic
value. Performance status 2 (P .006) and a higher number of metastatic sites (P .02) also
predicted shorter overall survival.
Conclusions
Pretreatment global QoL and IADL scores, but not ADL and comorbidity, have significant
prognostic value for survival of elderly patients with advanced non–small-cell lung cancer
who were treated with chemotherapy. Using these scores in clinical practice might improve
prognostic prediction for treatment planning.
J Clin Oncol 23:6865-6872. © 2005 by American Society of Clinical Oncology
INTRODUCTION
Non–small-cell lung cancer (NSCLC) is a
group of heterogeneous clinical entities with
different clinical behaviors and prognoses.
As is true for many other types of tumors,
the proportion of NSCLC patients aged 70
years or older is constantly increasing in in-
dustrialized countries because of the gain in
life expectancy observed in the second part
of the last century, and this trend is expected
to continue in the next decades.1
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In addition to classical prognostic factors for advanced
NSCLC including performance status (PS) and the extent of
disease,2 elderly cancer patients have peculiar characteristics
that may affect prognosis. In this regard, a pretreatment geri-
atric assessment, including evaluation of comorbidity, func-
tional status, depression, cognitive impairment, nutritional
status, and social support, hasbeenproposed to assess progno-
sis and predict toxicity.3-5 However, the advantage of such
a comprehensive assessment is probably outweighed by the
disadvantage of its poor applicability in clinical practice.
The assessment of comorbidity and the evaluation of
functional status are among the most important constituents
of a comprehensive geriatric assessment. Comorbiditymay be
summarized according to several scales.6,7 Functional status
refers to the ability of the patient to perform daily functions.
Assessment of PS is the most widely used functional score in
oncology, however, it has been suggested that this scoremight
underestimate the degree of functional impairment, particu-
larly in the elderly subset of patients.3 The most widely used
functional impairment geriatric scales are Katz’s basic Activi-
ties ofDaily Living (ADL)8 and Lawton’s9 Instrumental Activ-
ities of Daily Living (IADL). Although these geriatric scales
may produce additional information on the functional assess-
ment of elderly cancer patients, their prognostic role in elderly
patients with advanced NSCLC is unknown.
The Multicenter Italian Lung Cancer in the Elderly
Study–01 (MILES-01)10 was a large prospective random-
ized trial of chemotherapy dedicated to elderly patients with
advanced NSCLC. This study showed that polychemo-
therapy with gemcitabine plus vinorelbine was not more
effective than gemcitabine alone and vinorelbine alone. A
previous study by the same group of investigators,11 the
phase III Elderly Lung Cancer Vinorelbine Italian Study
(ELVIS) study, showed that vinorelbine was better than
supportive care in elderly patients with advanced NSCLC.
Also in that study, we found that the baseline scores of items
29 and 30 of the European Organisation for Research and
Treatment of Cancer (EORTC) core questionnaire QLQ-
C30 predicted time to dropout from the study; patients with
worse scores tended to drop out earlier than patients with
higher scores.11
The current study was planned a priori in the MILES
protocol to explore the possible prognostic role of ADL,
IADL, and comorbidity. Following the reported results of
the ELVIS study, we also included quality of life measured
with items 29 and 30 of EORTC QLQ-C30 as a covariate of
prognostic analysis.
PATIENTS AND METHODS
Patients and Treatment
Patients with advanced NSCLC enrolled onto the MILES
study10 were 70 years old or older, had stage IV or IIIB disease with
supraclavicular metastatic nodes or malignant pleural effusion,
and a baseline PS not worse than 2, according to the Eastern
Cooperative Oncology Group (ECOG) scale. The MILES study
compared the combination of vinorelbine and gemcitabine with
the two drugs given singly. Patients were randomly assigned to
receive vinorelbine (30 mg/m2), gemcitabine (1,200 mg/m2), or
gemcitabine (1,000 mg/m2) plus vinorelbine (25 mg/m2). All
treatments were administered on days 1 and 8 every 3 weeks for six
cycles of 21 days. The primary end point of the study was overall
survival. Of 707 patients randomly assigned between December
1997 and November 2000, 566 patients (80%) with complete
information on baseline ADL, IADL, and quality of life were
included in this prognostic analysis.
Global Health Status/Quality of Life
To assess quality of life, the EORTC QLQ-C3012 and the
EORTC lung cancer–specific module QLQ-LC1313 were used. In
the current analysis, only one score was used, the global health
status/quality of life (QoL), calculated with responses to items 29
and 30 of EORTC QLQ-C30. In response to these two items,
patients were asked to grade their global health status (item 29)
and quality of life (item 30) during the previous week on a scale of
7 points. A raw score was calculated for each patient and linearly
transformed in a percent scale ranging from 0 to 100, 0 represent-
ing the lowest level of global quality of life and 100 the highest. In
this analysis, patients were grouped in three score categories using
first and third quartiles as cut points: “better” (scoring  67%,
roughly representing the highest quarter of the distribution), “in-
termediate” (scoring 43% to 67%, about half of subjects),
and “worse” (scoring  42%, representing the lowest quarter of
the distribution).
Geriatric Assessment
Concomitant pathologies were scored as absent/present us-
ing a predefined list of 33 possible diseases. Comorbidity was
summarized by the Charlson score,6 summing up data regarding
myocardial infarction, congestive heart failure, peripheral vascu-
lar disease, cerebral vascular disease, dementia, chronic obstruc-
tive pulmonary disease, connective tissue disease, ulcer disease,
mild liver disease and diabetes. The other pathologic conditions
(hemiplegia, moderate or severe renal disease, diabetes with organ
damage, any other cancer, moderate or severe liver disease, AIDS)
used to calculate the Charlson score were not taken into account
because they were precluded by exclusion criteria for the study.
Consequently, higher scores were rarely attained, and just four
categories were used in the analysis (0, 1, 2, 3).
Functional status of elderly patients was measured by ADL
and IADL scores that were recorded at baseline, before random-
ization, by physicians.
ADL8 includes bathing, dressing, using the bathroom, conti-
nence, getting up and being able to move around the house, and
feeding. For each of the six items, twopossible scoreswere assigned: 0
(dependent)or1 (independent).Thus, theADLscore foreachpatient
ranged from 0 (unable to perform any activity) to 6 (able to perform
all activities). Becauseof thehighprevalenceof patients scoring6, two
groups were arbitrarily created for this analysis: fully independent
(score 6) and 1 dependency (scores 6).
IADL9 includes the ability to use the telephone, shopping,
food preparation, housekeeping, handyman work, laundry, the
ability to get around outside the home, responsibility for own
medications, and the ability to handle finances. For each item
four responses are available, three representing varying degrees
of dependency (all assigned score 0) and one representing full
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independency (score 1). Some of the explored domains (eg,
cooking, washing clothes, and so on) are fully applicable only to
women, considering the advanced age of the population. Thus,
missing data within the forms were frequent among men. To
accommodate this phenomenon, a raw score was calculated
considering only questions that had been answered by the
patients, on the assumption that missing values were primarily
due to inapplicability of the question. Such score was linearly
transformed in a percent scale ranging from 0 to 100, 0 repre-
senting the lowest level of ability and 100 the highest. For
prognostic and correlation analyses, patients were arbitrarily
grouped in three score categories: “better” (scoring 100%,
roughly representing the best quarter), “intermediate” (scoring
51% to 99%, about half of the subjects), and “worse” (scoring
0% to 50%, representing the worst quarter).
Statistical Methods
Associations between baseline ADL, IADL, and QoL catego-
ries and characteristics of patients were studied by contingency
tables and the 2 test.
Overall survival was defined as the time elapsed from the date
of randomization to the date of death or the date of the last
follow-up for patients alive at the end of the study. Multivariate
survival analysis was done using the Cox model,14 and was strati-
fied by treatment arm. Because of the high number of events, a
simple strategy was undertaken by a single model including
all known or potential prognostic factors (age, sex, stage, histo-
type, number of sites of disease, baseline QoL, ADL, IADL, and
Charlson score) and a variable representing institutions by num-
ber of patients enrolled ( 10, 10-29,  30) as a possibly con-
founding covariate. The likelihood ratio test was used to test the
contribution of each variable to themodel when added last, that is
after adjustment for all of the other covariates. P values less than
.05were considered statistically significant. Overall survival curves
were drawn by the Kaplan-Meier method.15
RESULTS
Patient Characteristics
Median age of the patients was 74 years (range, 70 to 84
years); 229 patients (40%) were 75 years old or older (Table
1). Men represented 82% of the population. Institutions that
enrolledmore than 30 patients comprised about one fourth of
the patients; those that enrolled between 10 and 29 patients
comprised about half the patients.
More patients with stage IV disease than stage III dis-
ease were enrolled, representing 69% of the sample (Table
2). Squamous cell carcinoma was the most prevalent histo-
logic type (45% of patients), followed by adenocarcinoma
(34%). Patients had a median of three organs affected by
cancer. Nineteen percent of patients had a deteriorated
baseline PS (ECOG category 2). Approximately 90% of the
patients had at least one and approximately 40% had three
ormore comorbidities; only 11%of patients had no comor-
bidity. According to the Charlson score, 42% of patients
were in the lowest category (score 0).
QoL, ADL, IADL, and Charlson score
Distribution of baseline QoL, ADL, and IADL in the
population is illustrated in Figure 1. QoL was distributed
symmetrically, with the majority of patients reporting in-
termediate scores. Conversely, both ADL and IADL distri-
butions were highly skewed, the best score being most
frequent (85% and 33% for ADL and IADL, respectively).
PS was significantly correlated with QoL, ADL, and
IADL scores. All the scores were worse among patients with
PS2 (Table 2; all P values .0001), whereas Charlson score
Table 1. Distribution of Baseline ADL, IADL, and QoL by Characteristics of Patients, Size of Institution, and Assigned Treatment
Variable
QoL ADL IADL
Total
(n  566)
Worse
(n  153)
Intermediate
(n  294)
Better
(n  119)
 1
Dependency
(n  84)
Fully
Independent
(n  482)
Worse
(n  161)
Intermediate
(n  217)
Better
(n  188)
No. % No. % No. % No. % No. % No. % No. % No. % No. %
Age, years
 75 89 58 177 60 71 60 51 61 286 59 88 55 136 63 113 60 337 60
75-79 56 37 109 37 45 38 28 33 182 38 66 41 72 33 72 38 210 37
 80 8 5 8 3 3 2 5 6 14 3 7 4 9 4 3 2 19 3
Sex
Male 117 77 244 83 104 87 71 85 394 82 145 90 176 81 144 77 465 82
Female 36 23 50 17 15 13 13 15 88 18 16 10 41 19 44 23 101 18
Center by No. of patients
 10 31 20 91 31 26 22 15 18 133 28 43 27 40 18 65 35 148 26
10-29 77 50 119 40 63 53 41 49 218 45 71 44 111 51 77 41 259 46
 30 45 30 84 29 30 25 28 33 131 27 47 29 66 30 46 24 159 28
Assigned treatment
Vinorelbine 49 32 102 35 41 34 35 42 157 33 57 35 74 34 61 32 192 34
Gemcitabine 54 35 95 32 38 32 20 24 167 35 53 33 70 32 64 34 187 33
Combination 50 33 97 33 40 34 29 34 158 33 51 32 73 34 63 34 187 33
NOTE. Boldfaced numbers are statistically significant.
Abbreviations: ADL, Activities of Daily Living; IADL, Instrumental Activities of Daily Living; QoL, Quality of Life.
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was only associated with IADL, being lower in patients with
higher IADL scores (P .005).
Overall Survival
Of 566 patients eligible for prognostic analysis, 462
patients (82%) died. Median overall survival for patients was
30 weeks (95% CI, 28 to 34), and 6-month and 1-year proba-
bilities of overall survival were 0.56 and 0.32, respectively.
Results of multivariate analysis are reported in Table 3.
After adjusting for the other covariates, QoL and IADLwere
associated with prognosis (P  .0003 and P  .04, respec-
tively), whereas ADL was not (P  .44). A low PS (ECOG
score 2) and the number of metastatic sites also indepen-
dently predicted worse overall survival rates (P .006 and
P  .02, respectively). Charlson score was not associated
with prognosis; the results were superimposible if the total
number of comorbidities was used instead of the Charlson
score. Kaplan-Meier–estimated overall survival curves for
QoL and IADL are shown in Figure 2.
DISCUSSION
A significant amount of both clinical and basic research has
focused on the prognostic factors for patients with NSCLC.
Although the prognosis of patientswith advancedNSCLC is
ominous overall, the identification of prognostic factors can
be useful, not only for providing important information to
the patients, but also for the correct choice of treatment.
The latter issue is particularly relevant for elderly patients,
because of the concerns about generalizability of treatment
effects demonstrated in younger patients16 and poor toler-
ability of treatments.
Within a secondary analysis of the MILES study, we
looked fornewtools topredict theprognosisof elderlypatients
at the time of diagnosis and before chemotherapy treatment.
Specifically, we studied the prognostic value of the patient’s
self-assessment of QoL and physician’s assessment of func-
tional scales (ADL and IADL) and comorbidity.
As for comorbidity, we recognize that a limitation of
the present study consists of the use of a qualitative yes/no
checklist, which does not result in information about the
severity of concomitant diseases. This choice was pragmat-
ically based on the principle of reducing the time needed to
assess patients at baseline. A similar scale has been used
previously by Repetto et al.5 The Charlson score,6 which
was used as a summary measure of comorbidity, revealed
no prognostic value in the MILES study. Although the
potential prognostic role of the Charlson score was limited
by the fact that eligibility criteria of the study excluded
patients with higher scores, this finding is consistent with
those recently reported by Janssen-Heijnen et al 17 showing
that among 4,072 patients diagnosed with NSCLC in the
Table 2. Distribution of Baseline ADL, IADL, and QoL by Characteristics of Disease, Performance Status, and Charlson Score
Variable
QoL ADL IADL
Total
(n  566)
Worse
(n  153)
Intermediate
(n  294)
Better
(n  119)
 1
Dependency
(n  84)
Fully
Independent
(n  482)
Worse
(n  161)
Intermediate
(n  217)
Better
(n  188)
No. % No. % No. % No. % No. % No. % No. % No. % No. %
Stage
IIIB 41 27 95 32 42 35 24 29 154 32 52 32 75 35 51 27 178 31
IV 112 73 199 68 77 65 60 71 328 68 109 68 142 65 137 73 388 69
Histology
Squamous 58 38 148 50 46 39 37 44 215 45 69 43 98 45 85 45 252 45
Adenocarcinoma 59 39 90 31 45 38 34 41 160 33 57 35 70 32 67 36 194 34
Other histology 36 23 56 19 28 23 13 15 107 22 35 22 49 23 36 19 120 21
No. of metastatic sites
1 4 3 8 3 3 3 2 2 13 3 4 2 6 3 5 3 15 3
2 42 27 100 34 45 38 27 32 160 33 46 29 77 35 64 34 187 33
3 63 41 121 41 33 28 38 45 179 37 71 44 75 35 71 38 217 38
4 29 19 49 17 25 21 10 12 93 19 29 18 41 19 33 18 103 18
 5 15 10 16 5 13 11 7 8 37 8 11 7 18 8 15 8 44 8
Performance status
0-1 111 73 236 80 113 95 47 56 413 86 101 63 190 88 169 90 460 81
2 42 27 58 20 6 5 37 44 69 15 60 37 27 12 19 10 106 19
Charlson score
0 67 44 111 38 59 50 35 42 202 42 54 34 85 39 98 52 237 42
1 50 33 121 41 39 33 27 32 183 38 64 40 84 39 62 33 210 37
2 30 20 47 16 15 13 17 20 75 16 37 23 35 16 20 11 92 16
 3 6 4 15 5 6 5 5 6 22 54 6 4 13 6 8 4 27 5
NOTE. Boldfaced numbers are statistically significant.
Abbreviations: QoL, Quality of Life; ADL, Activities of Daily Living; IADL, Instrumental Activities of Daily Living.
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Netherlands between 1995 and 1999, the number of comor-
bidities (collected according to a slightly modified version
of the Charlson score) had no prognostic value for overall
survival. A possible explanation of the lack of prognostic
relevance of comorbidity in advanced lung cancer is re-
ported in a recent paper by Read et al.18 The authors found
that among 11,558 cancer patients, concurrent comorbidi-
ties had no relevant prognostic impact for groups of pa-
tients with the lowest overall survival rates, including 1,005
patients with advanced lung cancer. Whether different and
more detailed definitions of comorbidity can produce use-
ful prognostic information in the setting of advanced
NSCLC remains to be seen.19,20 However, a study by Piccir-
illo et al21 of elderly patients with head and neck cancer
suggests that general comorbidity indexes (like the Charl-
son score) perform similarly to disease-specific comorbid-
ity indexes, and both types of scores are only able to weakly
predict prognosis.
In contrast with the established prognostic value of
ADL in nononcologic geriatric patients,22 baseline ADLhad
no prognostic value in the MILES population. A possible
explanation could be that the prognostic value of ADL, as
that of comorbidity,18 may only be truly effective in popu-
lations with a life expectancy longer than that of patients
with advanced NSCLC. In addition, we should consider
that dependencies in ADL represent quite severe deficien-
cies that probably prevent patients from being considered
Fig 1. Distribution of (A) quality of life (QoL), (B) Activities of Daily Living
(ADL), and (C) instrumental ADL (IADL). QoL and IADL values are linear
transformations of the raw scores.
Table 3. Multivariate Analysis
Variable HR
95% CL
P Upper Lower
Sex .07
Male (n  465) Ref
Female (n  101) 0.78 0.59 1.02
Age, years .69
 75 (n  337) Ref
75-79 (n  210) 1.09 0.89 1.32
 80 (n  19) 0.96 0.57 1.64
Performance status .006
0-1 (n  460) Ref
2 (n  106) 1.46 1.12 1.88
Charlson score .66
0 (n  237) Ref
1 (n  210) 1.06 0.85 1.32
2 (n  92) 1.12 0.85 1.48
 3 (n  27) 0.84 0.52 1.36
ADL .44
No dependence (n  482) Ref
One or more dependence (n  84) 1.12 0.85 1.47
IADL .04
Better (n  188) Ref
Intermediate (n  217) 0.97 0.76 1.22
Worse (n  161) 1.31 1.00 1.71
Quality of Life .0003
Better (n  119) Ref
Intermediate (n  294) 1.62 1.24 2.10
Worse (n  153) 1.76 1.29 2.39
Stage .71
IIIb (n  178) Ref
IV (n  388) 1.04 0.85 1.28
Histotype .17
Other (n  314) Ref
Squamous (n  252) 1.14 0.94 1.39
No. of sites of disease .02
For each added site 1.13 1.02 1.24
Center by No. of enrolled patients .09
 10 (n  148) Ref
10-29 (n  259) 1.19 0.94 1.52
 30 (n  159) 1.34 1.03 1.74
Abbreviations: HR, Hazard ratio of death; CL, confidence limits; Ref,
reference category; ADL, Activities of Daily Living; IADL, Instrumental
Activities of Daily Living.
Likelihood ratio test.
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eligible for chemotherapy and for clinical trials. On the
contrary, we found that baseline IADL had an independent
prognostic role, that appears mostly relevant for the lower
quarter, ie, the worse category. IADL is a quite easy-to-use
instrument, but its application is limited by the fact that
some domains (eg, cooking, washing clothes, and so on) are
not effectively applicable to male patients, particularly if
they are elderly. To accommodate this phenomenon, we
ignored missing data and calculated a raw score based on
available answers; this might reduce reproducibility of the
present result.
Another important observation of our study was that
baseline self-assessment of QoL, with two simple questions,
was the strongest prognostic factor among elderly patients
with advanced NSCLC enrolled onto the MILES trial; the
major difference being evident between the upper quarter
(ie, the better category) and the other categories that appear
to have similar prognosis. To our knowledge, the present
study reports the largest analysis on the prognostic role of
QoL score in advanced NSCLC and the first analysis on the
important subset of elderly patients. Indeed, Ganz et al23
reported on the importance of the Functional Living Index–
Cancer24 in 40 patients. Montazeri et al25 reported that in a
series of 129 patients global QoL measured by the EORTC
C-30 questionnaire was significantly lower among the 30
patients who died within 3 months, as compared with the
rest of the patients in the study. Langendijk et al26 reported
similar results with the EORTC C-30 questionnaire with
patients with lung cancer undergoing potentially curative
radiation therapy. These results are in slight contrast with
the observations ofHerndon et al27 on 206 patients enrolled
onto the Cancer and Leukemia Group B 8931 trial; they
found that although several items of the EORTCC-30 ques-
tionnaire (including the overall QoL score) were correlated
with prognosis at univariate analysis, only the pain score
was retained in the final multivariate model.
In addition to providing crucial prognostic informa-
tion, QoL assessment may be useful to improve communi-
cation with the patient and help the clinician to design
tailored supportive treatments based on the correct identi-
fication of the overall burden of symptoms, the relative
importance given to each of them by the patient, and his or
her expectations regarding treatment’s efficacy. As an ex-
ample of poor patient-physician communication, even in
the setting of randomized clinical trials, we have recently
reported28 that pain measured by the pain scores included
in the EORTCC-30 and LC-13 questionnaires is frequently
undertreated by physicians, particularly when instrumental
staging is negative for bone metastases. Thus, we suggest
that the use of QoL instruments in clinical practice could
help physicians improve their control of the patient’s symp-
toms. Indeed, the feasibility and utility of a comprehensive
assessment of elderly cancer patients, also when based on
self-report methodology like QoL questionnaires, has been
proven.29
In conclusion, quality of life and functional status as-
sessment, by items 29 and 30 of the EORTC C-30 ques-
tionnare and the IADL scale, respectively, could be used in
clinical practice as prognostic factors to aid the selection of
elderly patients with advanced NSCLC for chemotherapy.
■ ■ ■
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Az Ospedaliera “Bianchi-Melacrino-Morelli”, Reggio Cala-
bria (Giampietro Gasparini,¶ Alessandro Morabito,¶ Do-
menico Gattuso). *Experimental Medical Oncology,
Oncologic Institute, Bari (Giuseppe Colucci, Domenico
Galetta, Francesco Giotta). *Medical Oncology, University
of Palermo (Vittorio Gebbia). *La Maddalena Hospital,
Palermo (Nicola Borsellino, Antonio Testa). *S Vincenzo
Hospital, Taormina–CT (Francesco Ferrau`, Emilia
Malaponte). Thoracic Surgery, University of Foggia
(Matteo A. Capuano, Michele Angiolillo, Francesco
Sollitto). Medical Oncology, CRO, Aviano–PN (Umberto
Tirelli, Alessandra Bearz, Simona Spazzapan). Medical On-
cology, University of Messina (Vincenzo Adamo, Giuseppe
Altavilla, Antonino Scimone). Pneumology, University of
Palermo (Mario Spatafora, Maria Raffaella Hopps,
Francesco Tartamella). G. Rummo Hospital, Benevento
(Giovanni Pietro Ianniello, Vincenza Tinessa). S Luigi and
S.S. Curro` Gonzaga Hospital, Catania (Giuseppe Failla,
Roberto Bordonaro). Chemotherapy, University of Pal-
ermo (Nicola Gebbia, Maria Rosaria Valerio). *S Maria
Goretti Hospital, Latina (Modesto D’Aprile, Enzo Veltri),
Latina. Medical Oncology, University of Perugia (Maurizio
Tonato, Samir Darwish). *Cardarelli Hospital, Campo-
basso (Sante Romito, Francesco Carrozza). S Gerardo Hos-
pital, Monza–MI (Sandro Barni,# Antonio Ardizzoia).
USSL 33, Rho–MI (Giuliana Mara Corradini, Gianfranco
Pavia). *Civil Hospital, Avellino (Mario Belli, Giuseppe
Colantuoni). S Chiara Hospital, Trento (Enzo Galligioni,
OrazioCaffo).MedicalOncology, Spedali Riuniti, Bergamo
(Roberto Labianca, Antonello Quadri). Medical Oncology,
University La Sapienza, Roma (Enrico Cortesi, Giuliana
D’Auria). Civil Hospital, Legnano– MI (Sergio Fava, Anna
Calcagno). S Carlo Borromeo Hospital, Milano (Gino
Luporini, M. Cristina Locatelli). S Maria Hospital, Terni
(Francesco Di Costanzo, Silvia Gasperoni). Serbelloni Hos-
pital, Gorgonzola–MI (Luciano Isa, Paola Candido). USSL
15, Camposampiero–PD (Fernando Gaion, Giovanni
Palazzolo). *Miulli Hospital, Acquaviva delle Fonti–BA
(Giuseppe Nettis, Anselmo Annamaria). *Medical Oncol-
ogy II, “Regina Elena” Institute, Roma (Massimo Rinaldi,
Massimo Lopez). S Martino Hospital, Genova (Raffaella
Felletti, Giorgio Bernabo` Di Negro). *Civil Hospital, Pol-
la–SA (Nestore Rossi, Antonio Calandriello). San Gennaro
Hospital, Napoli (Luigi Maiorino). S Croce Hospital,
Fano–PS (Rodolfo Mattioli). S Giovanni Hospital, Torino
(Alfredo Celano). S Bortolo Hospital, Vicenza (Stefania
Schiavon). Oncology, Monaldi Hospital, Napoli (Alfonso
Illiano). Cottolengo Hospital, Torino (Carlo Alberto
Raucci). *Oncologic Center, Catania (Michele Caruso).
Medical Oncology, University of Milano (Paolo Foa).
Medical Oncology, Biomedical Campus, Roma (Giuseppe
Tonini). Thoracic Surgery, Ascalesi Hospital, Napoli (Carlo
Curcio††). Civil Hospital, Treviglio–BG (Marina
Cazzaniga). Pneumology, Spedali Riuniti, Bergamo. Medi-
cal Oncology I, IST, Genova. *Fatebenefratelli Hospital,
Benevento. *MedicalOncology, University of Cagliari. Bus-
inco Hospital, Cagliari. Agnelli Hospital, Pinerolo– TO. SS
Trinita` Hospital, Sora–FR. S Andrea Hospital, Vercelli.
Civil Hospital, Gorizia. Medical Oncology, University of
Sassari. Civil Hospital, Bolzano. Fortunato Hospital, Rion-
ero in Vulture–PZ. *Da Procida Hospital, Salerno. C Cantu`
Hospital, Abbiategrasso–MI. Pugliese CiaccioHospital, Ca-
tanzaro. Civil Hospital, Rovigo. S Maria delle Grazie Hos-
pital, Pozzuoli–NA. Civil Hospital, S Felice a Cancello–CE.
*Galateo Hospital, S.Cesareo–LE. Civil Hospital, Lagone-
gro–PZ. *Civil Hospital, Sciacca–AG.
NOTE: (*) denotes Institutions that participate in the
activities of the Gruppo Oncologico Italia Meridionale; (†)
S Giuseppe Moscati Hospital, Avellino; (‡)DaProcida Hos-
pital, Salerno; (§) S Gerardo Hospital, Monza; () S Paolo
Hospital, Milano; (¶) S Filippo Neri Hospital, Roma; (#)
Civil Hospital, Treviglio (BG); (**) S Giovanni di Dio e
Ruggi d’Aragona, Salerno; (††) Monaldi Hospital, Napoli.
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